查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835254

幽門螺旋桿菌非侵入性檢測市場（按檢測類型、技術、最終用戶和分銷管道）－全球預測，2025-2032

Helicobacter Pylori Non-invasive Testing Market by Test Type, Technology, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，非侵入性幽門螺旋桿菌檢測市場將成長至 17.8 億美元，複合年成長率為 5.88%。

主要市場統計數據
基準年2024年 11.2億美元
預計2025年 11.9億美元
預測年份：2032年 17.8億美元
複合年成長率（%） 5.88%

簡要介紹非侵入性幽門螺旋桿菌診斷、臨床相關性、病患治療路徑以及相關人員不斷變化的決策前景

幽門螺旋桿菌的非侵入性檢測已成為消化不良、消化性潰瘍及相關胃部疾病診斷途徑的重要組成部分，這源於人們在保持診斷準確性的同時盡量減少侵入性內視鏡操作的需求。這些檢測透過提供適合門診病人工作流程、基層醫療機構和分散式實驗室網路的替代方案，提高了患者的便利性並減輕了操作負擔。臨床醫生在選擇診斷工具時，越來越重視靈敏度、特異性、週轉時間和患者依從性，這些因素正在影響整個醫療保健系統的採購和臨床路徑決策。

隨著技術和臨床指南的不斷發展，非侵入性診斷的決策格局也在改變。付款人和醫療系統需要證據將檢測策略與患者結果和下游資源利用聯繫起來。因此，製造商和實驗室必須提供清晰的臨床檢驗、與現有設備的操作相容性，以及將結果整合到電子健康記錄的途徑。這些趨勢旨在擴大非侵入性檢測作為適當臨床環境中一線診斷工具的作用，同時保留用於複雜或難治病例的內視鏡檢測。

技術創新、檢測分散化以及臨床指引的變化如何重塑醫療環境中的非侵入性幽門螺旋桿菌診斷

隨著技術進步、分散式醫療模式以及注重準確性和患者便利性的更新臨床指南的融合，非侵入性幽門螺旋桿菌檢測的格局正在改變。免疫測量平台的快速改進，加上質譜和光譜分析方法的進步，正在提升分析性能並縮短週轉時間。同時，數位化工作流程和遠端檢體採集正在將檢測範圍從傳統的醫院實驗室擴展到基層醫療機構和居家醫療機構，從而影響臨床醫生的採用和患者的參與。

監管部門對臨床檢驗和可重複性的重視，促使製造商投資於強力的證據方案，而付款方的審查則加速了對健康經濟合理性的需求。隨著臨床醫師逐漸適應非侵入性治療方案，醫療路徑的平衡正被重新平衡。低風險患者擴大採用依賴高性能非侵入性檢測的「檢測-治療」策略進行管理，而內視鏡檢查則僅用於高風險或診斷可疑的病例。這種系統轉變為能夠證明臨床嚴謹性、易用性以及與分散式檢測環境相容性的診斷服務提供者創造了新的機會。

評估 2025 年美國新關稅對診斷相關人員、定價動態和策略採購的連鎖影響。

美國2025年實施的新關稅立即對整個診斷供應鏈產生了連鎖反應，改變了採購行為和策略採購決策。某些檢測耗材、設備和組件的進口關稅上調，增加了許多中小型實驗室的到岸成本，促使採購團隊重新評估其供應商組合，並優先考慮擁有本地生產設施和替代物流策略的供應商。這種轉變導致實驗室更加重視供應鏈透明度和合約彈性，以降低價格波動並維持病患服務的連續性。

為了應對這種情況，一些製造商加快了近岸外包，並實現了供應商多元化，以降低跨境貿易摩擦的風險。對於依賴專用試劑和儀器組件的診斷開發商而言，關稅使得他們更加重視長期供應商關係和垂直整合，並將其作為風險規避策略。同時，付款人和醫療保健採購委員會也更加關​​注整體擁有成本，包括缺貨和前置作業時間獎勵，並投資於區域供應彈性，從而保障臨床的連續性並維持可靠的非侵入性檢測的可及性。

跨測試類型、技術、最終用戶和分銷管道的高級細分洞察揭示了臨床採用、採購行為和創新路徑

了解市場動態需要採用多層次的細分方法，將測試效能與臨床用例和採購邏輯連結。依測試類型，有血清學測試、糞便抗原測試和尿素呼吸檢測。血清學測試細分為 IgA、IgG 和 IgM 檢測，而糞便抗原測試包括單株和多多株抗體方法。雖然血清學測試很方便，但它們可能反映過去的暴露，而不是活動性性行為感染。由於單克隆和多克隆抗體試劑化學性質的差異，糞便抗原測試可提供活動性性行為感染的直接證據，而尿素呼氣測試如果操作正確，可以以非侵入性的方式確認活動性性行為感染，並且特異性很強。

從技術角度來看，市場涵蓋免疫檢測平台、紅外線光譜和質譜。免疫檢測選項進一步細分為 ELISA 和快速免疫檢測，而質譜則以 GC-MS 和 LC-MS 為代表。每種技術類別都需要在通量、靈敏度、儀器佔地面積和資本強度之間進行權衡。最終用戶包括診所、診斷實驗室和醫院。診所分為胃腸病診所和基層醫療診所，醫院分為二級和三級醫療中心。分銷管道正在不斷發展，包括線下和線上通路。線上通路支援將套件直接銷售給消費者，並為機構買家快速補貨。整合這些細分視角可以明確臨床需求和採購標準的交匯點，以及創新可以在哪些方面提供差異化的臨床和營運價值。

美洲、中東和非洲以及亞太地區的區域動態和差異化招募模式

非侵入性幽門螺旋桿菌檢測的區域動態受醫療保健基礎設施、報銷標準、臨床實踐模式和法律規範差異的影響。美洲地區在門診病人網路和綜合醫療保健系統中擴大採用經過驗證的非侵入性診斷方法，並積極努力使檢測途徑與初級保健工作流程保持一致。在歐洲、中東和非洲，由於法規環境和報銷政策的差異，一些市場正在迅速採用先進技術，而其他市場則優先考慮能夠滿足基本診斷需求的經濟高效的檢測方法。

隨著人們對胃腸道疾病流行病學認知的不斷提高、診斷檢測能力的不斷提升以及對即時醫療服務的重視，亞太地區正在加速非侵入性檢測方案的普及。製造商和經銷商必須根據當地報銷慣例和臨床醫生的偏好，客製化其臨床證據包、定價模式和服務能力。因此，跨國公司通常會採取差異化的上市策略，與當地實驗室和國內分銷商合作，以確保符合監管規定，並根據每個細分市場的具體需求客製化產品定位。

非侵入性幽門螺旋桿菌診斷生態系中關鍵參與者、創新者和專業領域的競爭定位和能力評估

非侵入性幽門螺旋桿菌診斷領域的競爭態勢由眾多知名儀器製造商、專業試劑供應商以及開發照護現場或分散式解決方案的敏捷創新者共同構成​​。關鍵競爭因素包括臨床檢驗的深度、分銷的廣度、服務和培訓能力，以及與實驗室資訊系統和電子健康記錄整合的能力。能夠展示穩健性能數據、強大的上市後監測和可靠供應營運的公司將獲得採購團隊和實驗室管理人員的優先事項。

技術創新也在改變競爭定位。對於尋求簡化工作流程的診所和診斷實驗室而言，那些投資於連接複用功能、提高檢測靈敏度和特異性以及簡化樣本採集套件的公司越來越有吸引力。儀器製造商和試劑供應商之間的策略夥伴關係，以及與受託研究機構合作進行臨床檢驗，是加速市場滲透的常見策略。此外，提供全面客戶支援（包括臨床教育和實施服務）的組織通常能夠建立超越一次性採購交易的長期組織關係。

診斷生態系領導者必須採取有針對性的策略行動，以加速診斷的採用，確保供應彈性，並最佳化診斷商業化的臨床證據生成

診斷生態系統領導者應優先考慮一系列有針對性的行動，以利用需求變化並降低營運風險。首先，投資符合當地監管要求的嚴格臨床檢驗研究，可以增強臨床醫生的信心並提高付款人的接受度。這些研究必須證明其在護理過程中具有明確的臨床效用，而不僅僅是分析性能。其次，透過近岸外包、雙重採購和策略性庫存夥伴關係等方式實現製造和供應商關係的多元化，可以減少關稅造成的成本衝擊和物流中斷的風險。

第三，加強數位化和直接面對消費者的管道，將實現高效的檢體追蹤和結果交付，同時擴大患者的可及性。第四，及早與付款方和衛生技術評估機構溝通，明確報銷標準，並提供真實世界證據，將有助於實現可預測的採用。最後，與實驗室和臨床網路建立合作項目，以進行持續的市場研究和迭代式產品改進，將保持競爭優勢。將這些行動結合起來，將創造一個兼顧技術創新、營運可靠性和以付款方為導向的證據產生能力的彈性商業模式。

透過結合臨床醫生訪談、臨床實驗室檢驗、監管映射和三重二手資料的強大調查方法來獲得嚴謹的見解

支持這些發現的研究將定性一手研究與結構化的二次研究以及方法學保障措施相結合，以確保信度和效度。一手研究包括對臨床相關人員（包括胃腸病學家、基層醫療醫生、實驗室主任和採購專業人員）的深入訪談，以了解決策因素、臨床工作流程和應用障礙。這些對話指導了對現實世界診斷路徑的解讀，並有助於確定技術和最終用戶的重點領域，以便進一步研究。

二次研究涵蓋同行評審文獻、監管指南文件、技術白皮書和製造商技術規範，以支持臨床和技術聲明。監管圖譜確定了國家核准途徑和上市後要求，而對近期專利申請和學術論文的審查則闡明了技術創新的軌跡。數據合成依靠三角測量來協調來源之間的不一致，並建構連貫的敘述。品質保證步驟包括對關鍵發現進行專家檢驗，以及對主題結論進行敏感性檢查，以確保建議在不同的臨床和營運環境下均具有穩健性。

綜合策略意義、臨床發展動能和市場準備情況，強調非侵入性幽門螺旋桿菌檢測相關人員的關鍵要點

幽門螺旋桿菌的非侵入性診斷技術正處於曲折點，技術進步、醫療服務分散化以及監管力度的加強正在共同重塑臨床實踐。檢測效能的提升、可及途徑的拓展以及付款人對臨床效用日益成長的興趣，共同為將非侵入性檢測更一致地納入診斷方案創造了條件。相關人員協調臨床檢驗、供應彈性和付款人參與的利害關係人，將最有可能影響醫療保健途徑，並確保其在不同醫療環境中持續應用。

展望未來，持續重視證據生成和操作與實際臨床實務的整合，將決定哪些技術能獲得長期臨床應用。積極滿足臨床醫生需求、簡化工作流程並展示非侵入性檢測以患者為中心的優勢的製造商和實驗室，很可能獲得最廣泛的受眾。最終，最成功的策略將是那些在科學嚴謹性與成本、可及性和易實施性等實際因素之間取得平衡的策略，從而為患者提供更好的治療結果，並為醫療保健提供者提供更可預測的運作。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 擴大採用智慧型手機整合尿素呼吸檢測來快速檢測門診幽門螺旋桿菌
  • 擴大多重糞便抗原檢測以提高菌株鑑別和抗生素抗藥性分析的敏感度
  • 人工智慧預測演算法的出現，可以解釋非侵入性測試結果並預測治療結果
  • 開發一種針對幽門螺旋桿菌的 POC層析法檢測方法，以提高資源有限地區的準確性和成本效益
  • 糞便 DNA 甲基化分析在幽門螺旋桿菌感染非侵入性檢測和個人化管理的應用日益廣泛
  • 在低至中等盛行率族群中，非侵入性診斷途徑與內視鏡檢查相比的成本效益分析
  • 採用非放射性同位素技術的新型呼吸檢測套件的監管核准和打入市場策略

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 幽門螺旋桿菌非侵入性檢測市場（依檢測類型）

  • 血清學檢測
    • IGa測試
    • 免疫球蛋白G檢測
    • IGm測試
  • 糞便抗原檢測
    • 單株抗體檢測
    • 多株抗體檢測
  • 尿素呼氣試驗

9. 幽門螺旋桿菌非侵入性檢測市場（依技術）

  • 免疫檢測
    • 伊麗莎
    • 快速免疫檢測
  • 紅外線光譜
  • 質譜法
    • GC-MS
    • LC-MS

第 10 章。非侵入性幽門螺旋桿菌檢測市場（按最終用戶）

  • 診所
    • 胃腸病診所
    • 基層醫療診所
  • 診斷實驗室
  • 醫院
    • 二級護理醫院
    • 三級醫院

第 11 章。非侵入性幽門螺旋桿菌檢測市場（按分銷管道）

  • 離線
  • 線上

12. 幽門螺旋桿菌非侵入性檢測市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 13 章。 幽門螺旋桿菌無創檢測市場（按組）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 幽門螺旋桿菌非侵入性檢測市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • bioMerieux SA
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • QIAGEN NV
    • DiaSorin SpA
    • Meridian Bioscience, Inc.
    • SD BIOSENSOR Co., Ltd.
Product Code: MRR-437E9896A586

The Helicobacter Pylori Non-invasive Testing Market is projected to grow by USD 1.78 billion at a CAGR of 5.88% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.12 billion
Estimated Year [2025] USD 1.19 billion
Forecast Year [2032] USD 1.78 billion
CAGR (%) 5.88%

A concise orientation to non-invasive Helicobacter pylori diagnostics, clinical relevance, patient pathways, and the evolving decision landscape for stakeholders

Non-invasive testing for Helicobacter pylori has become a pivotal component of diagnostic pathways for dyspepsia, peptic ulcer disease, and related gastric disorders, driven by the need to minimize invasive endoscopic procedures while preserving diagnostic accuracy. These tests improve patient convenience and reduce procedural burden by offering alternatives that are compatible with outpatient workflows, primary care settings, and decentralized laboratory networks. Clinicians increasingly weigh sensitivity, specificity, turnaround time, and patient adherence when selecting a diagnostic modality, and these factors shape procurement and clinical pathway decisions across healthcare systems.

As technology and clinical guidelines evolve, the decision landscape for non-invasive diagnostics is also shifting. Payers and health systems seek evidence that links testing strategies to patient outcomes and downstream resource utilization. Consequently, manufacturers and laboratories must present clear clinical validation, operational compatibility with existing instrumentation, and pathways to integrate results into electronic health records. Together, these trends are aligning to expand the role of non-invasive testing as a first-line diagnostic tool in appropriate clinical scenarios, while preserving endoscopy for complex or refractory cases.

How technological innovation, decentralization of testing, and changing clinical guidelines are reshaping non-invasive Helicobacter pylori diagnosis across care settings

The landscape of non-invasive Helicobacter pylori testing is being transformed by a convergence of technological advances, decentralized care models, and updated clinical guidance that privileges precision and patient convenience. Rapid improvements in immunoassay platforms, coupled with advances in mass spectrometry and spectrometric approaches, are enhancing analytical performance while enabling shorter turnaround times. Simultaneously, digital workflows and remote specimen collection are expanding access beyond traditional hospital laboratories and into primary care and home-based settings, which in turn influences clinician adoption and patient engagement.

Regulatory emphasis on clinical validation and reproducibility is encouraging manufacturers to invest in robust evidence packages, and payer scrutiny is accelerating the demand for health-economic justification. As clinicians adapt to non-invasive alternatives, pathways of care are being rebalanced: patients with low-risk presentations are increasingly managed with test-and-treat strategies that rely on high-performing non-invasive assays, while endoscopy is conserved for high-risk or ambiguous cases. These systemic shifts are creating new opportunities for diagnostics providers who can demonstrate clinical rigor, ease of use, and compatibility with decentralized testing environments.

Assessing the cascading effects of new United States tariff measures enacted in 2025 on supply chains, pricing dynamics, and strategic sourcing for diagnostics stakeholders

The introduction of new tariff measures in the United States in 2025 had immediate ripple effects across the diagnostics supply chain, altering procurement behavior and strategic sourcing decisions. Increased import duties on certain laboratory consumables, instruments, and components elevated landed costs for many small and mid-sized laboratories, prompting procurement teams to re-evaluate supplier portfolios and prioritize vendors with local manufacturing footprints or alternative logistics strategies. These shifts have placed a premium on supply chain transparency and contractual flexibility as laboratories seek to mitigate price volatility and maintain continuity of patient-facing services.

In response, some manufacturers accelerated nearshoring and diversified supplier bases to reduce exposure to cross-border trade frictions. For diagnostic developers that rely on specialized reagents or instrumentation components, the tariffs intensified the focus on long-term supplier relationships and vertical integration as risk-reduction tactics. Meanwhile, payers and provider procurement committees have become more attentive to the total cost of ownership, including the operational impacts of stockouts and lead-time variability. Overall, the tariff environment has strengthened incentives to de-risk sourcing, optimize inventory strategies, and invest in regional supply resilience to protect clinical continuity and preserve access to reliable non-invasive testing.

Nuanced segmentation insight across test types, technologies, end users, and distribution channels illuminating clinical adoption, procurement behavior, and innovation pathways

Understanding market dynamics requires a layered segmentation approach that links test performance to clinical use cases and procurement logic. By test type, offerings span serology tests, stool antigen tests, and urea breath tests; serology is sub-segmented into IgA, IgG, and IgM assays, while stool antigen methodologies include monoclonal and polyclonal antibody approaches. Each test type carries distinct clinical attributes: serology can be convenient but may reflect past exposure rather than active infection, stool antigen assays offer direct evidence of active infection with variations between monoclonal and polyclonal reagent chemistry, and urea breath tests provide non-invasive confirmation of active infection with robust specificity when conducted appropriately.

From a technology perspective, the market encompasses immunoassay platforms, infrared spectrometry, and mass spectrometry, with immunoassay options further divided into ELISA and rapid immunoassay modalities, and mass spectrometry techniques represented by GC-MS and LC-MS approaches. Each technological class presents trade-offs between throughput, sensitivity, equipment footprint, and capital intensity. End users include clinics, diagnostic laboratories, and hospitals; clinics segment into gastroenterology clinics and primary care clinics, while hospitals can be classified as secondary care and tertiary care institutions. Distribution channels are evolving and include both offline and online routes, with online channels enabling direct-to-consumer kit distribution and rapid supply replenishment for institutional buyers. Integrating these segmentation lenses clarifies where clinical demand intersects with procurement criteria and where innovation can yield differentiated clinical and operational value.

Regional dynamics and differentiated adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific that inform commercial and clinical strategies

Regional dynamics in non-invasive Helicobacter pylori testing are shaped by differences in healthcare infrastructure, reimbursement norms, clinical practice patterns, and regulatory frameworks. In the Americas, there is strong uptake of validated non-invasive diagnostics within outpatient networks and integrated health systems, accompanied by active efforts to align testing pathways with primary care workflows. In Europe, Middle East & Africa, heterogeneous regulatory environments and varied reimbursement policies lead to pronounced country-level differences, where some markets adopt advanced technologies rapidly while others prioritize cost-effective assays that meet essential diagnostic needs.

Across the Asia-Pacific region, rising awareness of gastric disease epidemiology, expanding diagnostic laboratory capacity, and an emphasis on point-of-care accessibility are accelerating adoption of non-invasive testing options. These regional distinctions inform go-to-market strategies: manufacturers and distributors must tailor clinical evidence packages, pricing models, and service capabilities to local reimbursement realities and clinician preferences. Consequently, global players often pursue differentiated launch approaches, partnering with regional laboratories or in-country distributors to ensure regulatory alignment and to adapt product positioning to the specific needs of each market cluster.

Competitive positioning and capability assessment of leading players, innovators, and niche specialists in non-invasive Helicobacter pylori diagnostics ecosystems

Competitive dynamics in the non-invasive Helicobacter pylori diagnostics space are defined by a mix of established instrument manufacturers, specialized reagent suppliers, and agile innovators developing point-of-care or decentralizable solutions. Key competitive levers include the depth of clinical validation, the breadth of distribution networks, service and training capabilities, and the ability to integrate with laboratory information systems and electronic health records. Companies that can demonstrate robust performance data, strong post-market surveillance, and reliable supply operations gain preferential consideration from procurement teams and laboratory directors.

Innovation is also reshaping competitive positioning: firms that invest in multiplexing capabilities, improvements in assay sensitivity and specificity, and streamlined sample collection kits are increasingly attractive to clinics and diagnostic laboratories seeking to simplify workflows. Strategic partnerships between instrument makers and reagent vendors, as well as alliances with contract research organizations for clinical validation, are common strategies to accelerate market penetration. Moreover, organizations that provide comprehensive customer support, including clinical education and implementation services, often secure longer-term institutional relationships that extend beyond single-purchase transactions.

Targeted strategic actions for industry leaders to accelerate adoption, secure supply resilience, and optimize clinical evidence-generation for diagnostics commercialization

Leaders in the diagnostics ecosystem should prioritize a set of targeted actions to capitalize on shifting demand and to mitigate operational risks. First, investing in rigorous clinical validation studies that align with local regulatory expectations will accelerate clinician trust and payer acceptance; these studies should demonstrate not only analytical performance but also clear clinical utility within care pathways. Second, diversifying manufacturing and supplier relationships-whether through nearshoring, dual sourcing, or strategic inventory partnerships-will reduce exposure to tariff-induced cost shocks and logistical disruptions.

Third, strengthening digital and direct-to-consumer channels can expand patient access while enabling efficient specimen tracking and result delivery. Fourth, engaging early with payers and health technology assessment bodies to clarify reimbursement criteria and to present real-world evidence will support predictable adoption. Finally, establishing collaborative programs with laboratories and clinical networks for ongoing post-market surveillance and iterative product improvement will sustain competitive differentiation. Taken together, these actions create a resilient commercial model that balances innovation with operational reliability and payer-aware evidence generation.

Robust research methodology combining clinician interviews, laboratory validation review, regulatory mapping, and triangulated secondary intelligence for rigorous findings

The research underpinning these insights combines qualitative primary engagement, structured secondary review, and methodological safeguards to ensure reliability and relevance. Primary research included in-depth interviews with clinical stakeholders such as gastroenterologists, primary care physicians, laboratory directors, and procurement professionals to capture decision drivers, clinical workflows, and adoption barriers. These conversations informed the interpretation of real-world diagnostic pathways and guided the selection of technology and end-user focus areas for deeper investigation.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, technical white papers, and manufacturer technical specifications to corroborate clinical and technical assertions. Regulatory mapping identified local approval pathways and post-market requirements, while a review of recent patent filings and academic publications highlighted innovation trajectories. Data synthesis relied on triangulation across sources to reconcile discrepancies and to build a coherent narrative. Quality assurance steps included expert validation of key findings and sensitivity checks on thematic conclusions to ensure that recommendations remain robust across diverse clinical and operational contexts.

Synthesis of strategic implications, clinical momentum, and market readiness that distills key takeaways for stakeholders in non-invasive Helicobacter pylori testing

Non-invasive diagnostics for Helicobacter pylori are at an inflection point where technological improvements, decentralized care delivery, and heightened regulatory scrutiny converge to reshape clinical practice. The combined momentum of improved assay performance, expanded access pathways, and payer attention to clinical utility creates conditions for more consistent incorporation of non-invasive tests into diagnostic algorithms. Stakeholders that align clinical validation, supply resilience, and payer engagement will be best positioned to influence care pathways and to secure durable adoption across diverse healthcare settings.

Looking ahead, continued emphasis on real-world evidence generation and operational integration will determine which technologies achieve long-term clinical traction. Manufacturers and laboratories that proactively address clinician needs, streamline workflows, and demonstrate the patient-centered benefits of non-invasive testing will find the most receptive audiences. Ultimately, the most successful strategies will balance scientific rigor with practical considerations of cost, access, and ease of implementation to support better outcomes for patients and more predictable operational performance for healthcare providers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of smartphone integrated urea breath tests for rapid Helicobacter pylori detection in outpatient settings
  • 5.2. Expansion of multiplex stool antigen assays with enhanced sensitivity for strain differentiation and antibiotic resistance profiling
  • 5.3. Emergence of AI powered predictive algorithms to interpret noninvasive test results and forecast treatment efficacy
  • 5.4. Development of point of care immunochromatographic tests for Helicobacter pylori with improved accuracy and affordability in resource limited regions
  • 5.5. Increasing incorporation of stool DNA methylation analysis for noninvasive detection and personalized management of Helicobacter pylori infection
  • 5.6. Cost effectiveness analysis of noninvasive diagnostic pathways compared to endoscopy in low to moderate prevalence populations
  • 5.7. Regulatory approvals and market entry strategies for novel breath test kits utilizing non radioactive isotope technology

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Helicobacter Pylori Non-invasive Testing Market, by Test Type

  • 8.1. Serology Test
    • 8.1.1. IGa Test
    • 8.1.2. IGg Test
    • 8.1.3. IGm Test
  • 8.2. Stool Antigen Test
    • 8.2.1. Monoclonal Antibody Test
    • 8.2.2. Polyclonal Antibody Test
  • 8.3. Urea Breath Test

9. Helicobacter Pylori Non-invasive Testing Market, by Technology

  • 9.1. Immunoassay
    • 9.1.1. Elisa
    • 9.1.2. Rapid Immunoassay
  • 9.2. Infrared Spectrometry
  • 9.3. Mass Spectrometry
    • 9.3.1. Gc Ms
    • 9.3.2. Lc Ms

10. Helicobacter Pylori Non-invasive Testing Market, by End User

  • 10.1. Clinics
    • 10.1.1. Gastroenterology Clinic
    • 10.1.2. Primary Care Clinic
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
    • 10.3.1. Secondary Care Hospital
    • 10.3.2. Tertiary Care Hospital

11. Helicobacter Pylori Non-invasive Testing Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Helicobacter Pylori Non-invasive Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Helicobacter Pylori Non-invasive Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Helicobacter Pylori Non-invasive Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. F. Hoffmann-La Roche AG
    • 15.3.2. Abbott Laboratories
    • 15.3.3. bioMerieux SA
    • 15.3.4. Danaher Corporation
    • 15.3.5. Thermo Fisher Scientific Inc.
    • 15.3.6. Siemens Healthineers AG
    • 15.3.7. QIAGEN N.V.
    • 15.3.8. DiaSorin S.p.A.
    • 15.3.9. Meridian Bioscience, Inc.
    • 15.3.10. SD BIOSENSOR Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. EU